Overview

• U.S. cell therapy developer's Q1 net loss narrowed from prior year

• Lower R&D and G&A expenses drove reduced net loss in Q1

• Company expects cash reserves to fund operations into second half of 2027

Outlook

• Adicet expects to provide a clinical update for prula-cel in autoimmune diseases in mid-2026

• Company plans FDA meeting in 2Q/2026 to inform potential pivotal trial design for prula-cel

• Adicet aims to submit regulatory filing for ADI-212 in mCRPC in 3Q/2026; enrollment may begin 4Q/2026

Result Drivers

• LOWER R&D EXPENSES - Co said Q1 R&D expenses fell due to lower headcount, reduced lab supply costs, and decreased CRO expenses

• REDUCED G&A COSTS - Co attributed lower G&A expenses to decreased payroll, stock-based compensation, and facility-related costs

Company press release: ID:nBw6WSwrMa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Adicet Bio Inc is $22.50, about 183% above its May 12 closing price of $7.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.